nach oben

Current Atherosclerosis Reports

Erschienen in:

01.04.2013 | Coronary Heart Disease (JA Farmer, Section Editor)

Ambulatory Blood Pressure Improves Prediction of Cardiovascular Risk: Implications for Better Antihypertensive Management

verfasst von: Lawrence R. Krakoff

Erschienen in: Current Atherosclerosis Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Accurate measurement of arterial pressure is necessary for diagnosis of hypertension and for assessment of its therapy. The development and growing application of ambulatory blood pressure monitoring (ABPM) furthers these goals. Use of ABPM has defined white coat hypertension (WCH) and masked hypertension (MH), important prognostic diagnoses. ABPM categorizes blood pressure in several ways that increase accuracy for diagnosis and prediction of cardiovascular risk. Measurements of blood pressure throughout the day, at night during sleep, during the morning surge, and, in some instances selected intervals can be especially valuable for both research and clinical management. ABPM is being explored for its value in measuring pulse pressure and a derived index of arterial stiffness. ABPM has also shown to be valuable for defining the effects of antihypertensive drugs therapy. Results of such studies are crucial for advancing antihypertensive management. This review will summarize the important and emerging role of ABPM in defining risk for cardiovascular disease.

Sokolow M, Werdegar D, Kain HK, Hinman AT. Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension. Circulation. 1966;34(2):279–98.PubMedCrossRef

Perloff D, Sokolow M, Cowan R. The prognostic value of ambulatory blood pressures. JAMA. 1983;249:2792–8.PubMedCrossRef

•• Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891. Sumarizes the UK incorporation into national guidelines. PubMedCrossRef

McManus RJ, Caulfield M, Williams B. NICE hypertension guideline 2011: evidence based evolution. BMJ. 2012;344:e181.PubMedCrossRef

•• Fagard R. Reappraisal of the European guidelines on hypertension management: the European Society of Hypertension Task Force document: a short review. Pol Arch Med Wewn. 2010;120(1-2):31–5. Updates the European guidelines, including recommendations for use of ABPM and normal values. PubMed

Head GA, Mcgrath BP, Mihailidou AS, Nelson MR, Schlaich MP, Stowasser M, et al. Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. J Hypertens. 2012;30(2):253–66. Another national guideline recommending a role for ABPM. PubMedCrossRef

Pickering TG, Harshfield GA, Kleinert HD, Blank S, Laragh JH. Blood pressure during normal daily activities, sleep, and exercise. JAMA. 1982;247:992–6.PubMedCrossRef

Owens P, O'Brien E. Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events? Heart. 1999;82(4):477–81.PubMed

Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46(1):156–61.PubMedCrossRef

10.

Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793–801.PubMedCrossRef

11.

Redon J, Campos C, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 2001;31:712–8.CrossRef

12.

Clement D, De Buyzere M, De Bacqer DA, de Leeuw PW, Duprez DA, Fagard RH, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–15.PubMedCrossRef

13.

Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47(5):846–53.PubMedCrossRef

14.

Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Telera MP, Pede S, et al. Adverse prognostic value of a blunted circadian rhythm of heart rate in essential hypertension. J Hypertens. 1998;16(9):1335–43.PubMedCrossRef

15.

Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55–61.PubMedCrossRef

16.

• Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension. 2012;60(1):34–42. Increased risk in a prospective study was related to a lesser fall in pressure during sleep (non-dipper), and a lesser increase with awakening in the non-dippers as well. Increased risk was not related to those with greater morning surges. PubMedCrossRef

17.

Veerman DP, Imholz BB, Wieling W, Wesseling KH, van-Montfrans GA. Circadian profile of systemic hemodynamics. Hypertension. 1995;26:55–9.PubMedCrossRef

18.

Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142–61.PubMed

19.

Chobanian AV, Bakris GL, Black HR, Green L, Jr Izzo JL, Jones DW, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and treatment of high blood pressure: the JNC 7 Report. JAMA. 2003;289:2560–72.PubMedCrossRef

20.

Vasan RS, Larson MG, Leip E, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study. Lancet. 2001;358:1682–6.PubMedCrossRef

21.

Mancia G, Bertinieri G, Grassi G, Pomidossi G, Ferrari A, Gregorini L, et al. Effects of blood pressure measurement by the doctor on patient’s blood pressure and heart rate. Lancet. 1983;2:695–8.PubMedCrossRef

22.

Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA. 1988;259:225–8.PubMedCrossRef

23.

Hoegholm A, Kristensen KS, Madsen NH, Svendsen TL. White coat hypertension diagnosed by 24-h ambulatory monitoring. Am J Hypertens. 1992;5:64–70.PubMed

24.

•• Pickering TG, Gerin W, Schwartz JE, Spruill TM, Davidson KW. Franz Volhard lecture: should doctors still measure blood pressure? The missing patients with masked hypertension. J Hypertens. 2008;26(12):2259–67. This is a very important summary of the most relevant research and application of the WCH and MH conepts. PubMedCrossRef

25.

Bruce NG, Shaper AG, Walker M, Wannamethee G. Observer bias in blood pressure studies. J Hypertens. 1988;6:375–80.PubMedCrossRef

26.

Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150(4):341–53.PubMedCrossRef

27.

Turner MJ, van Schalkwyk JM. Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study. Am J Hypertens. 2008;21(1):85–91.PubMedCrossRef

28.

Moore CR, Krakoff LR, Phillips RA. Confirmation or exclusion of stage I hypertension by ambulatory blood pressure monitoring. Hypertension. 1997;29:1109–13.PubMedCrossRef

29.

Krakoff LR. Cost-effectiveness of ambulatory blood pressure: a reanalysis. Hypertension. 2006;47(1):29–34.PubMedCrossRef

30.

•• Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FR, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet 2011;378:1219–30. The most up to date and relevant look at how ABPM can be cost-effective.

31.

Kotsis V, Stabouli S, Toumanidis S, Papamichael C, Lekakis J, Germanidis G, et al. Target organ damage in “white coat hypertension” and “masked hypertension”. Am J Hypertens. 2008;21(4):393–9.PubMedCrossRef

32.

Ruddy MC, Bialy GB, Malka ES, Lacy CR, Kostis JB. The relationship of plasma renin activity to clinic and ambulatory blood pressure in elderly people with isolated systolic hypertension. J Hypertens. 1988;6:S412–5.

33.

Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45(2):203–8.PubMedCrossRef

34.

Mallion JM, Clerson P, Bobrie G, Genes N, Vaisse B, Chatellier G. Predictive factors for masked hypertension within a population of controlled hypertensives. J Hypertens. 2006;24(12):2365–70.PubMedCrossRef

35.

• Pierdomenico SD, Cuccurullo F. Ambulatory blood pressure monitoring in type 2 diabetes and metabolic syndrome: a review. Blood Press Monit. 2010;15(1):1–7. Excellent summary of ABPM studies in these two very important groups. PubMedCrossRef

36.

Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med. 1999;131:564–72.PubMed

37.

Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004;291(11):1342–9.PubMedCrossRef

38.

Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2003;14:1263–9.CrossRef

39.

Mezzetti A, Pierdomenico SD, Costantini F, Romano F, Bucci A, DiGioacchino M, et al. White-coat resistant hypertension. Am J Hypertens. 1997;10(1302):1307.

40.

O’Brien E. Ambulatory blood pressure measurement: the case for implementation in primary care. Hypertension. 2008;51(6):1435–41.PubMedCrossRef

41.

Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168(21):2340–6.PubMedCrossRef

42.

• Ahmed MI, Pisoni R, Calhoun DA. Current options for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther. 2009;7(11):1385–93. This report highlights the need for defining resistant hypertension accurately and separating from pseudo-resistant hypertension. PubMedCrossRef

43.

Logan AG, Perlikowski SM, Mente A, Tisler A, Tkcova R, Niroumand M, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2003;19:2271–7.CrossRef

44.

• Hermida RC, Ayala DE, Mojon A, Fontao MJ, Fernandez JR. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int. 2011;28(7):601–10. An interesting study that supports the case for nocturnal administration of some antihypertensive drugs. PubMedCrossRef

45.

• Mallick SR, Rahman M. Nocturnal medications dosing: does it really make a difference in blood pressure control among patients with chronic kidney disease? Curr Hypertens Rep. 2012;14(5):449–54. This review summarizes the evidence that, in chronic renal disease, nocturnal hypertension increases for disease outcome, but also admits that no current dosing scheme is superior for reducing outcomes. The need for well focused trials to solve this problem is emphasized. PubMedCrossRef

46.

Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38(4):852–7.PubMedCrossRef

47.

Ingelsson E, Bjorklund-Bodegard K, Lind L, Arnlov J, Sundstrom J. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA. 2006;295(24):2859–66.PubMedCrossRef

48.

Cuspidi C, Meani S, Lonati L, Fusi V, Valerio C, Sala C, et al. Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients. J Hypertens. 2006;24(4):647–53.PubMedCrossRef

49.

Wilcox I, Grunstein RR, Hedner JA, Doyle J, Collins FL, Fletcher PJ. Effect of nasal continuous positive airway pressure during sleep on 24-hour blood pressure in sleep apnea. Sleep. 1993;16:539–44.PubMed

50.

• Hermida RC, Chayan L, Ayala DE, Mojon A, Fontao MJ, Fernandez JR. Relationship between metabolic syndrome, circadian treatment time, and blood pressure non-dipping profile in essential hypertension. Chronobiol Int. 2011;28(6):509–19. This study links abnormalities in diurnal pressure rhythm and the, high risk, metabolic syndrome. PubMedCrossRef

51.

Suzuki M, Otsuka K, Guilleminault C. Long-term nasal continuous positive airway pressure administration can normalize blood pressure in obstructive sleep apnea patients. Sleep. 1993;16:545–9.PubMed

52.

Ceruti M, Petramala L, Cotesta D, Cerci S, Serra V, Caliumi C, et al. Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal diseases. J Clin Hypertens (Greenwich ). 2006;8(9):642–8.CrossRef

53.

Imai Y, Abe K, Sasaki S, Minami N, Nihei M, Munakata M, et al. Altered circadian blood pressure rhythm in patients with Cushing’s Syndrome. Hypertension. 1988;12:11–9.PubMedCrossRef

54.

Davidson MB, Hix JK, Vidt DG, Brotman DJ. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med. 2006;166(8):846–52.PubMedCrossRef

55.

Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117(5):603–24.PubMed

56.

Krasinska B, Karolczak-Kulesza M, Krasinski Z, Pawlaczyk-Gabriel K, Niklas A, Gluszek J, et al. A marked fall in nocturnal blood pressure is associated with the stage of primary open-angle glaucoma in patients with arterial hypertension. Blood Press 2010;20:171–81. This study links extreme dipper status with a serious threat to vision, independent of cardiovascular disease.

57.

Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA. 2003;289:2073–82.PubMedCrossRef

58.

White WB, Baker LH. Episodic hypertension secondary to panic disorder. Arch Intern Med. 1986;146:1129–30.PubMedCrossRef

59.

Fujishima S, Abe I, Kaseda S, Koga T, Hirano H, Hamada T, et al. Ambulatory blood pressure monitoring in diagnosing a pheochromocytoma of the urinary bladder. A case report. Angiology. 1997;48(7):655–8.PubMedCrossRef

60.

Gallen IW, Taylor RS, Salzmann MB, Tooke JE. Twenty-four hour ambulatory blood pressure and heart rate in a patient with a predominantly adrenaline secreting phaeochromocytoma. Postgrad Med J. 1994;70(826):589–91.PubMedCrossRef

61.

Meisel SR, Mor-Avi V, Rosenthal T, Akselrod S. Spectral analysis of the systolic blood pressure signal in secondary hypertension: a method for the identification of phaeochromocytoma. J Hypertens. 1994;12(3):269–75.PubMedCrossRef

62.

Mak G, Murphy NF, Ali A, Walsh A, O'Loughlin C, Conlon C, et al. Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much? J Card Fail. 2008;14(7):555–60.PubMedCrossRef

63.

• Franklin SS, Lopez VA, Wong ND, Mitchell GF, Larson MG, Vasan RS, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119(2):243–50. This study Identifies the importance of pulse pressure as a contributor to prognosis. PubMedCrossRef

64.

•• Ungar A, Pepe G, Lambertucci L, Fedeli A, Monami M, Mannucci E, et al. Low diastolic ambulatory blood pressure is associated with greater all-cause mortality in older patients with hypertension. J Am Geriatr Soc. 2009;57(2):291–6. This is an important study for how ABPM might be helpful in detecting excessively low blood pressure in a high-risk population, the elderly. PubMedCrossRef

65.

• Li Y, Wang JG, Dolan E, Gao PJ, Guo HF, Nawrot T, et al. Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring. Hypertension. 2006;47(3):359–64. Arterial stiffness is now of great interest and concern. This report defines a derived estimate based on ABPM recording, a new approach. PubMedCrossRef

66.

• Dolan E, Thijs L, Li Y, Atkins N, McCormack P, McClory S, et al. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension. 2006;47(3):365–70. Should be read with #65 to see how the arterial stiffness index can be a predictor of cardiovascular disease. PubMedCrossRef

67.

Palmas W, Pickering TG, Teresi J, Schwartz JE, Moran A, Weinstock RS, et al. Ambulatory blood pressure monitoring and all-cause mortality in elderly people with diabetes mellitus. Hypertension. 2009;53(2):120–7.PubMedCrossRef

68.

Aznaouridis K, Vlachopoulos C, Protogerou A, Stefanadis C. Ambulatory systolic-diastolic pressure regression index as a predictor of clinical events: a meta-analysis of longitudinal studies. Stroke. 2012;43(3):733–9.PubMedCrossRef

69.

Matsui Y, O'Rourke MF, Ishikawa J, Shimada K, Kario K. Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study. Am J Hypertens. 2012;25(8):862–8.PubMedCrossRef

70.

Gimpel C, Wuhl E, Arbeiter K, Drozdz D, Trivelli A, Charbit M, et al. Superior consistency of ambulatory blood pressure monitoring in children: implications for clinical trials. J Hypertens. 2009;27(8):1568–74.PubMedCrossRef

71.

Conway J, Johnston J, Coats A, Somers V, Sleight P. The use of ambulatory blood pressure monitoring to improve the accuracy and reduce the numbers of subjects in clinical trials of antihypertensive agents. J Hypertens. 1988;6:111–6.PubMedCrossRef

72.

• Mancia G, Parati G, Bilo G, Gao P, Fagard R, Redon J, et al. Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension 2012;60:1400–6. This is an important sub-study using ABPM in a sample of participants from the very large ONTARGET trial. The results suggest that in those at high risk of cardiovascular disease due to diabetes, hypertension, and target organ damage, small differences in systolic pressure among groups were not predictive of outcomes.

73.

•• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. Renal denervation is a new and promising therapy for resistant hypertension. Evidence from ABPM is crucial for assessing therapy as clinic pressures alone may magnify differences in pressure. PubMedCrossRef

74.

Pickering TG, Miller NH, Ogedegbe G, Krakoff LR, Artinian NT, Goff D. Call to Action on Use and Reimbursement for Home Blood Pressure Monitoring: Executive Summary. A Joint Scientific Statement From the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:1–8.PubMedCrossRef

75.

• Krakoff LR. Home blood pressure for the management of hypertension: will it become the new standard of practice? Expert Rev Cardiovasc Ther. 2011;9(6):745–51. Home blood pressure monitoring is a growing and appealing technology. This is a recent comprehensive review for comparison of surveys of ABPM. PubMedCrossRef

76.

•• McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010;376(9736):163–72. Results of a trial of self care and home blood pressure monitoring, possibly a paradigm of future management of hypertension. PubMedCrossRef

77.

Krakoff LR. Management of cardiovascular risk factors is leaving the office: potentional impact of telemedicine. J Clin Hypertens (Greenwich ). 2011;13:791–4.CrossRef

78.

O’Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005;23(4):697–701.PubMedCrossRef

79.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26.PubMedCrossRef

Titel: Ambulatory Blood Pressure Improves Prediction of Cardiovascular Risk: Implications for Better Antihypertensive Management
verfasst von: Lawrence R. Krakoff
Publikationsdatum: 01.04.2013
Verlag: Current Science Inc.
Erschienen in: Current Atherosclerosis Reports / Ausgabe 4/2013
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-013-0317-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Metformin Therapy in Diabetes: The Role of Cardioprotection

The Cholesterol Emboli Syndrome in Atherosclerosis

Medical Management of Stable Coronary Atherosclerosis

Aggressive Statin Therapy and the Risk of Malignancy

Acute Coronary Syndromes: Advances in Antithrombotics